Furthermore, HtrA3 is an inhibitor of the bone morphogenetic protein pathway, linked to EMT [49], and has been implicated as a tumour suppressor gene during cancer progression in many cancers, such as lung cancer, ovarian cancer, breast cancer and colorectal cancer [49,50,51,52]. This evidence concerns the gene HTRA3 and ovarian cancer.